FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W170291259> ?p ?o ?g. }

• W170291259 abstract "The aim of this study was to evaluate the short and mid-term safety and efficacy of the EPIC™ nitinol vascular stent system for the treatment of lesions located in the superficial femoral artery (SFA).From October 2010 to June 2012, 83 subjects were enrolled in a prospective, multicenter, non-randomized study designed to demonstrate that the EPIC nitinol vascular stent system for SFA lesions is non-inferior to the published patency rates found in literature. Inclusion criteria were stenosis or occlusion of the SFA or SFA and proximal popliteal artery, with total length from 4 to 11 cm and amenable for treatment with a single stent, in patients with a score from 2 to 5 on Rutherford classification. The primary endpoint was primary patency rate at 12 months as determined by Duplex ultrasound. The secondary endpoints evaluated were: initial arteriographic success, primary patency rate at 6 months, major adverse event rate at one year and technical success. Follow-up with a complete clinical and physical exam, including ABI and Duplex ultrasound was performed at 6 and 12 months.Most patients (56.6%) were men and the mean age was 68.59 (33.1-99.15) years. 25.3% of the total population had intermittent claudication and 73.5% presented with critical limb ischemia. Most lesions were total occlusions (75.9%) and the mean lesion length was 71.16 mm. Contralateral femoral access was performed in 26.5%cases, and ipsilateral femoral approach was used for the remaining 73.5% patients. Technical and arteriographic success was obtained in all 83 (100.00%) patients. Duplex controlled primary patency rate at 6 and 12 months was 95.8% and 76.1%, respectively. The freedom from target lesion revascularization rate was 98.7% and 92.6% at 6 and 12 months, respectively. No stent fractures were observed in this study. Major adverse event rate at 1 year (clinically driven TLR, major amputation, and all-cause mortality) was 15.7%: two target lesion revascularizations (2.4%), one major amputation (1.2%) and ten deaths not related to the procedure (12%).In conclusion, this study demonstrates the safety and efficacy of the EPIC™ Nitinol Vascular Stent System for the treatment of SFA lesions." @default.
• W170291259 created "2016-06-24" @default.
• W170291259 creator A5001089626 @default.
• W170291259 creator A5004770489 @default.
• W170291259 creator A5009544053 @default.
• W170291259 creator A5013908509 @default.
• W170291259 creator A5021738353 @default.
• W170291259 creator A5028885825 @default.
• W170291259 creator A5031342838 @default.
• W170291259 creator A5032584613 @default.
• W170291259 creator A5033896525 @default.
• W170291259 creator A5034363474 @default.
• W170291259 creator A5038098008 @default.
• W170291259 creator A5038832072 @default.
• W170291259 creator A5043978290 @default.
• W170291259 creator A5048953542 @default.
• W170291259 creator A5051433675 @default.
• W170291259 creator A5055494472 @default.
• W170291259 creator A5059820053 @default.
• W170291259 creator A5060318415 @default.
• W170291259 creator A5061656616 @default.
• W170291259 creator A5072441111 @default.
• W170291259 creator A5072685513 @default.
• W170291259 creator A5072723353 @default.
• W170291259 creator A5080066478 @default.
• W170291259 creator A5081482593 @default.
• W170291259 creator A5084446855 @default.
• W170291259 creator A5088825671 @default.
• W170291259 date "2017-03-01" @default.
• W170291259 modified "2023-10-01" @default.
• W170291259 title "Safety and efficacy of the EPIC™ nitinol vascular stent system for the treatment of lesions located in the superficial femoral artery: prospective and multicentric trial" @default.
• W170291259 doi "https://doi.org/10.23736/s0021-9509.16.08471-8" @default.
• W170291259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25731858" @default.
• W170291259 hasPublicationYear "2017" @default.
• W170291259 type Work @default.
• W170291259 sameAs 170291259 @default.
• W170291259 citedByCount "4" @default.
• W170291259 countsByYear W1702912592015 @default.
• W170291259 countsByYear W1702912592018 @default.
• W170291259 countsByYear W1702912592020 @default.
• W170291259 crossrefType "journal-article" @default.
• W170291259 hasAuthorship W170291259A5001089626 @default.
• W170291259 hasAuthorship W170291259A5004770489 @default.
• W170291259 hasAuthorship W170291259A5009544053 @default.
• W170291259 hasAuthorship W170291259A5013908509 @default.
• W170291259 hasAuthorship W170291259A5021738353 @default.
• W170291259 hasAuthorship W170291259A5028885825 @default.
• W170291259 hasAuthorship W170291259A5031342838 @default.
• W170291259 hasAuthorship W170291259A5032584613 @default.
• W170291259 hasAuthorship W170291259A5033896525 @default.
• W170291259 hasAuthorship W170291259A5034363474 @default.
• W170291259 hasAuthorship W170291259A5038098008 @default.
• W170291259 hasAuthorship W170291259A5038832072 @default.
• W170291259 hasAuthorship W170291259A5043978290 @default.
• W170291259 hasAuthorship W170291259A5048953542 @default.
• W170291259 hasAuthorship W170291259A5051433675 @default.
• W170291259 hasAuthorship W170291259A5055494472 @default.
• W170291259 hasAuthorship W170291259A5059820053 @default.
• W170291259 hasAuthorship W170291259A5060318415 @default.
• W170291259 hasAuthorship W170291259A5061656616 @default.
• W170291259 hasAuthorship W170291259A5072441111 @default.
• W170291259 hasAuthorship W170291259A5072685513 @default.
• W170291259 hasAuthorship W170291259A5072723353 @default.
• W170291259 hasAuthorship W170291259A5080066478 @default.
• W170291259 hasAuthorship W170291259A5081482593 @default.
• W170291259 hasAuthorship W170291259A5084446855 @default.
• W170291259 hasAuthorship W170291259A5088825671 @default.
• W170291259 hasConcept C126322002 @default.
• W170291259 hasConcept C126838900 @default.
• W170291259 hasConcept C141071460 @default.
• W170291259 hasConcept C168563851 @default.
• W170291259 hasConcept C188816634 @default.
• W170291259 hasConcept C203092338 @default.
• W170291259 hasConcept C2776268601 @default.
• W170291259 hasConcept C2777466421 @default.
• W170291259 hasConcept C2778283817 @default.
• W170291259 hasConcept C2778583881 @default.
• W170291259 hasConcept C2778963770 @default.
• W170291259 hasConcept C2779723990 @default.
• W170291259 hasConcept C2780007028 @default.
• W170291259 hasConcept C2780400711 @default.
• W170291259 hasConcept C2781099653 @default.
• W170291259 hasConcept C2781464078 @default.
• W170291259 hasConcept C2908647359 @default.
• W170291259 hasConcept C3018348675 @default.
• W170291259 hasConcept C500558357 @default.
• W170291259 hasConcept C71924100 @default.
• W170291259 hasConcept C99454951 @default.
• W170291259 hasConceptScore W170291259C126322002 @default.
• W170291259 hasConceptScore W170291259C126838900 @default.
• W170291259 hasConceptScore W170291259C141071460 @default.
• W170291259 hasConceptScore W170291259C168563851 @default.
• W170291259 hasConceptScore W170291259C188816634 @default.
• W170291259 hasConceptScore W170291259C203092338 @default.
• W170291259 hasConceptScore W170291259C2776268601 @default.
• W170291259 hasConceptScore W170291259C2777466421 @default.
• W170291259 hasConceptScore W170291259C2778283817 @default.
• W170291259 hasConceptScore W170291259C2778583881 @default.
• W170291259 hasConceptScore W170291259C2778963770 @default.
• W170291259 hasConceptScore W170291259C2779723990 @default.

• next